Skip to Main Content

A plan to expand the use of Acadia Pharmaceuticals’ only approved medicine to cover the treatment of patients with schizophrenia was dealt a setback on Monday with the failure of a late-stage clinical trial, the company said.

The Acadia drug, called Nuplazid, failed to improve the overall symptoms of schizophrenia compared with a placebo. The Phase 3 study enrolled nearly 400 schizophrenia patients with moderate to severe psychotic symptoms inadequately controlled by currently approved drugs. 

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.